KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Marcia L. Lux(Brigham and Women's Hospital), Jonathan A. Fletcher(Harvard University), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Tara L. Biase(Brigham and Women's Hospital), George D. Demetri(Dana-Farber Cancer Institute), Samuel Singer(Memorial Sloan Kettering Cancer Center), Sheng Xiao(Brigham and Women's Hospital), Brian P. Rubin(Cleveland Clinic), Chang-Jie Chen(Brigham and Women's Hospital), Timothy Maclure(Brigham and Women's Hospital)
Cited by 647
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996